


Supplementary Figures

Figure A1. Survival of patients with glioblastoma, IDH-wildtype.

A: Overall survival.



B: Progression-free survival.






Figure A2. Survival of patients with glioblastoma, IDH-wildtype with respect to treatment regimen.


A: Overall survival: concurrent temozolomide vs. no concurrent temozolomide.




B: Overall survival: adjuvant temozolomide vs. no adjuvant temozolomide.




C: Overall survival: radiotherapy alone vs. radiotherapy with both concurrent and adjuvant temozolomide.



D: Progression-free survival: concurrent temozolomide vs. no concurrent temozolomide.



E: Progression-free survival: adjuvant temozolomide vs. no adjuvant temozolomide.



F: Progression-free survival: radiotherapy alone vs. radiotherapy with both concurrent and adjuvant temozolomide.






Figure A3. Progression-free survival with respect to *MGMT* promoter methylation.

A: Patients with glioblastoma, IDH-wildtype: *MGMT*-methylated vs. *MGMT*-unmethylated.



B: Patients with glioblastoma, IDH-wildtype, *MGMT*-methylated: temozolomide and radiotherapy vs. only radiotherapy.



C: Patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated: temozolomide and radiotherapy vs. only radiotherapy.






Figure A4. Survival with respect to treatment regimen and *MGMT* promoter methylation.


A: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated: concurrent temozolomide and no concurrent temozolomide.




B: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated: adjuvant temozolomide and no adjuvant temozolomide.




C: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated:
concurrent temozolomide and no concurrent temozolomide.




D: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-methylated:
adjuvant temozolomide and no adjuvant temozolomide.




E: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated:
concurrent temozolomide and no concurrent temozolomide.



F: Overall survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated: adjuvant temozolomide and no adjuvant temozolomide.



G: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated:
concurrent temozolomide and no concurrent temozolomide.



H: Progression-free survival patients with glioblastoma, IDH-wildtype, *MGMT*-unmethylated:
adjuvant temozolomide and no adjuvant temozolomide.






Figure A5. Survival with respect to tumors with *TERT* promoter mutated (*pTERTmt*) only.

A: Overall survival of patients with glioblastoma, IDH-wildtype: glioblastoma, IDH-wildtype, *pTERTmt* only vs. other glioblastoma, IDH-wildtype.




B: Progression-free survival of patients with glioblastoma, IDH-wildtype: glioblastoma, IDH-wildtype, *pTERTmt* only vs. other glioblastoma, IDH-wildtype.



C: Overall survival of patients with glioblastoma, IDH-wildtype, pTERTmt only:

temozolomide and radiotherapy vs. only radiotherapy.



D: Progression-free survival of patients with glioblastoma, IDH-wildtype, pTERTmt only:

temozolomide and radiotherapy vs. only radiotherapy.





Figure A6. Survival of patients with glioblastoma, IDH-wildtype: necrosis and/or microvascular proliferation vs. no necrosis or microvascular proliferation.

A: Overall survival.



B: Progression-free survival.

